|
US4189604A
(en)
|
1975-07-22 |
1980-02-19 |
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai |
Bestatin
|
|
CA1108180A
(en)
|
1976-07-21 |
1981-09-01 |
Hamao Umezawa |
Analogs of bestatin
|
|
US4117161A
(en)
|
1977-05-16 |
1978-09-26 |
Jose Pozuelo |
Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
|
|
US4165382A
(en)
|
1977-10-17 |
1979-08-21 |
Jose Pozuelo |
Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
|
|
US5206018A
(en)
|
1978-11-03 |
1993-04-27 |
Ayerst, Mckenna & Harrison, Inc. |
Use of rapamycin in treatment of tumors
|
|
US5683981A
(en)
|
1987-05-22 |
1997-11-04 |
Competitive Technologies, Inc. |
Cyclic bridged analogs of α-MSH and methods thereof
|
|
US5674839A
(en)
|
1987-05-22 |
1997-10-07 |
Competitive Technologies, Inc. |
Cyclic analogs of alpha-MSH fragments
|
|
US5073541A
(en)
|
1987-11-18 |
1991-12-17 |
Administrators Of The Tulane Educational Fund |
Treatment of small cell lung cancer with somatostatin analogs
|
|
US5225435A
(en)
|
1990-05-18 |
1993-07-06 |
Yale University |
Soluble melanin
|
|
WO1994022460A1
(en)
|
1993-04-05 |
1994-10-13 |
University Patents, Inc. |
Diagnosis and treatment of erectile dysfunction
|
|
IT1291633B1
(it)
|
1997-04-22 |
1999-01-11 |
Pharmaconsult S A S |
Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
|
|
US20030059471A1
(en)
|
1997-12-15 |
2003-03-27 |
Compton Bruce Jon |
Oral delivery formulation
|
|
NZ506839A
(en)
|
1998-03-09 |
2003-05-30 |
Zealand Pharma As |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
CA2341903A1
(en)
|
1998-08-21 |
2000-03-02 |
The Children's Medical Center Corporation |
Use of melanin for inhibition of angiogenesis and macular degeneration
|
|
US6498247B2
(en)
|
2000-04-13 |
2002-12-24 |
Pro-Health, Inc. |
Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions
|
|
US20030114362A1
(en)
|
2001-06-08 |
2003-06-19 |
Novaspin Biotech Gmbh |
Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
|
|
WO2004089918A1
(ja)
|
2003-04-09 |
2004-10-21 |
Japan Tobacco Inc. |
複素芳香５員環化合物及びその医薬用途
|
|
US20060088607A1
(en)
|
2004-10-01 |
2006-04-27 |
Stefano George B |
Nutritional supplement compositions
|
|
DE602005014442D1
(de)
|
2005-03-11 |
2009-06-25 |
Gpc Biotech Ag |
Antiproliferative Kombinations-Therapie mit Satraplatin oder JM118 und Docetaxel
|
|
CN101193626A
(zh)
|
2005-03-11 |
2008-06-04 |
益德威士医药股份有限公司 |
奥曲肽的受控释放制剂
|
|
WO2009054001A1
(en)
|
2007-10-22 |
2009-04-30 |
Biocon Limited |
A pharmaceutical composition and a process thereof
|
|
EP2262522A1
(en)
|
2008-03-07 |
2010-12-22 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
|
US20110098241A1
(en)
|
2008-04-14 |
2011-04-28 |
Poniard Pharmaceuticals, Inc. |
Rapamycin analogs as anti-cancer agents
|
|
US8003689B2
(en)
|
2008-06-20 |
2011-08-23 |
Gtx, Inc. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
|
US20110200556A1
(en)
|
2008-08-20 |
2011-08-18 |
The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi |
Chemoprevention of head and neck squamous cell carcinomas
|
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
BRPI1010655A2
(pt)
|
2009-04-10 |
2019-09-03 |
Qi Haiyan |
novos agentes antienvelhecimento e métodos para identificá-los
|
|
WO2011112576A1
(en)
|
2010-03-10 |
2011-09-15 |
Ambrilia Biopharma Inc. |
Microspheres for sustained release of octreotide acetate
|
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
|
WO2012123819A1
(en)
|
2011-03-15 |
2012-09-20 |
Optinose As Et Al |
Nasal delivery
|
|
PL220308B1
(pl)
|
2011-06-03 |
2015-10-30 |
Kobel Buys Krystyna |
Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
|
|
US20130183263A1
(en)
|
2012-01-17 |
2013-07-18 |
Steven Hoffman |
Pharmaceutical compositions and methods
|
|
US8481498B1
(en)
|
2012-01-17 |
2013-07-09 |
Steven Hoffman |
Pharmaceutical compositions and methods
|
|
US9763903B2
(en)
*
|
2013-10-22 |
2017-09-19 |
Steven Hoffman |
Compositions and methods for treating intestinal hyperpermeability
|
|
US10751313B2
(en)
*
|
2013-10-22 |
2020-08-25 |
Yamo Pharmaceuticals Llc |
Compositions and methods for treating autism
|
|
US9326962B2
(en)
*
|
2013-10-22 |
2016-05-03 |
Steven Hoffman |
Compositions and methods for treating intestinal hyperpermeability
|
|
US10813901B2
(en)
*
|
2013-10-22 |
2020-10-27 |
Yamo Pharmaceuticals Llc |
Compositions and methods for treating autism
|
|
US20150111878A1
(en)
|
2013-10-22 |
2015-04-23 |
Steven Hoffman |
Compositions and methods for treating intestinal hyperpermeability
|
|
MX2017013176A
(es)
|
2015-04-14 |
2018-01-30 |
Hoffman Steven |
Composiciones y metodos para tratar autismo.
|